Jonathan S. Vogelgsang

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Nick C Fox, Pavel P. Kuksa, W. M. van der Flier, 2022, Nature Genetics.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Keith A. Johnson, D. Y. Lee, W. M. van der Flier, 2022, JAMA neurology.

Novel Exosome Biomarker Candidates for Alzheimer’s Disease Unravelled Through Mass Spectrometry Analysis

C. B. da Cruz E Silva, F. Amado, J. Wiltfang, 2021, Molecular Neurobiology.

Diagnostic performance of automated plasma amyloid-β assays combined with pre-analytical immunoprecipitation

J. Schuchhardt, J. Wiltfang, S. Palme, 2022, Alzheimer's research & therapy.

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

W. M. van der Flier, D. Rujescu, I. Giegling, 2022, Acta Neuropathologica.

Bioinformatic analysis of the SPs and NFTs proteomes unravel putative biomarker candidates for Alzheimer's disease

J. Wiltfang, R. Vitorino, Niels Hansen, 2023, Proteomics.

Identification of risk factors for delirium, cognitive decline, and dementia after cardiac surgery (FINDERI—find delirium risk factors): a study protocol of a prospective observational study

C. Lange, J. Wiltfang, C. V. von Arnim, 2022, BMC Cardiovascular Disorders.

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

K. Blennow, L. Shaw, P. Lewczuk, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Detection and quantification of Aβ−3–40 (APP669‐711) in cerebrospinal fluid

J. Wiltfang, B. Mollenhauer, O. Wirths, 2022, Journal of neurochemistry.